logo

For the Inventor, By the Inventor

Zwijnaarde, Belgium

Argenx Bvba

USPTO Granted Patents = 13


Forward Citations = 19

Loading Chart...
Loading Chart...

40 inventors (with patents filed for the assignee):

goldMedal Torsten Dreier (7 out of 27 patents)

silverMedal Sebastian Paul Van Der Woning (7 out of 14 patents)

bronzeMedal Sophie Lucas (5 out of 21 patents)

4.  Gitte De Boeck (5 out of 5 patents)

5.  Pierre G Coulie (5 out of 53 patents)

6.  Michael Saunders (4 out of 13 patents)

7.  Johannes Joseph Wilhelmus De Haard (4 out of 34 patents)

8.  Hans De Haard (3 out of 20 patents)

9.  Christophe Blanchetot (3 out of 24 patents)

10.  Filip Borgions (3 out of 4 patents)

11.  Lore Mariën (3 out of 4 patents)

12.  Christophe Frederic Jerome Blanchetot (3 out of 12 patents)

13.  Julia Cuende Villasur (2 out of 3 patents)

14.  Natalie De Jonge (2 out of 10 patents)

15.  Peter Ulrichts (2 out of 10 patents)


13 patents:

1. 11230603 - Anti-GARP protein (2022-01-25),
2. 11161900 - Antibodies that specifically bind to human complement factor C2b (2021-11-02),
3. 11117959 - IL-6 binding molecules (2021-09-14),
4. 11072665 - Antibodies to CD70 (2021-07-27),
5. 10875914 - Nucleic acids encoding GARP-TGF-beta 1 antibodies (2020-12-29),
6. 10793627 - GARP-TGF-β 1 IGG antibodies (2020-10-06),
7. 10696741 - Anti-IL-22R antibodies (2020-06-30),
8. 10676535 - Anti c-Met antibodies (2020-06-09),
9. 10604579 - Antibody against a complex between human GARP and latent TGF-β (2020-03-31),
10. 10487156 - Asymmetric multispecific antibodies (2019-11-26),
11. 10479829 - GARP-TGF-beta 1 antibodies (2019-11-19),
12. 10316073 - FCRN antagonists and methods of use (2019-06-11),
13. 10040870 - Highly diverse combinatorial antibody libraries (2018-08-07),
Company Overview
Argenx Bvba is a biotechnology company based in Zwijnaarde, Belgium, specializing in the development of innovative therapies for the treatment of severe autoimmune diseases and cancer. The company focuses on harnessing the power of the immune system through its proprietary antibody engineering platform, which allows for the creation of differentiated therapeutic candidates. Argenx is committed to advancing its research in immunology and oncology, aiming to address unmet medical needs with its cutting-edge solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

13 Patents

#7 in Zwijnaarde

#214 in Belgium

#45,081 in the World

Zwijnaarde, BE
Zwijnaarde, Belgium

Argenx Bvba

Forward Citations = 19

40 inventors:

goldMedal Torsten Dreier (7 out of 27 patents)

silverMedal Sebastian Paul Van Der Woning (7 out of 14 patents)

bronzeMedal Sophie Lucas (5 out of 21 patents)

4.  Gitte De Boeck (5 out of 5 patents)

5.  Pierre G Coulie (5 out of 53 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Argenx Bvba. Retrieved from https://idiyas.com/company/argenx-bvba

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…